Research programme: antibacterials - Astellas Pharma/Sumitomo Dainippon Pharma

Drug Profile

Research programme: antibacterials - Astellas Pharma/Sumitomo Dainippon Pharma

Alternative Names: 2-aryl carbapenems; SM-295291; SM-368589; SM-369926; SM-375769

Latest Information Update: 17 Jul 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astellas Pharma; Dainippon Sumitomo Pharma
  • Developer Astellas Pharma; Sumitomo Dainippon Pharma
  • Class Carbapenems
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 20 Sep 2011 Preclinical development is ongoing Japan
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top